Explore personalized treatment options for stage 4 prostate cancer in Germany including dendritic cell therapy, TACP, and PSMA-based therapies with complete medical and travel support for international patients.
Stage 4 prostate cancer is an advanced condition in which cancer cells have spread beyond the prostate gland to distant organs such as the bones, liver, lungs, or lymph nodes. At this stage, treatment is no longer focused on cure but on slowing disease progression, relieving symptoms, and supporting the patient’s overall quality of life.
Stage 4 prostate cancer treatment options in Germany are recognized for their medical precision and commitment to patient-centered care. Under the supervision of experienced German specialists, patients receive access to Innovative Therapies for prostate cancer in Germany such as Dendritic Cell Immunotherapy, Lutetium-177 PSMA Therapy, and Actinium-225 PSMA Therapy.
Each of these therapies is designed to either stimulate the immune system or directly target metastatic cancer cells, offering a strategic approach to controlling disease progression. For international patients, treatment in Germany (TIG) ensures seamless coordination and complete logistic arrangements for patients, including travel, lodging, and medical visa for international patients (if required).
Metastatic or stage 4 prostate cancer occurs when cancer has extended beyond the prostate gland. The most common areas affected are the bones, particularly the spine and pelvis, as well as organs like the liver and lungs. Clinical symptoms depend on the extent and location of the disease and often include pain, urinary complications, and general fatigue.
In Germany, treatments are tailored to the patient’s specific condition using a combination of state-of-the-art diagnostics and personalized treatment plans. Modern therapies are focused on precision, minimizing side effects, and improving long-term outcomes.
Symptoms at this stage may include:
Close follow-up is essential. Rising PSA level after prostate cancer treatment is one of the earliest indicators of disease progression or recurrence. In German oncology centers, PSA monitoring is conducted alongside imaging to assess treatment effectiveness and guide timely interventions.
Why Patients Choose Germany for stage 4 Prostate Cancer treatment
Germany offers a structured and evidence-based model of cancer care. Hospitals operate under EU standards and are certified by the German Cancer Society. Each patient is evaluated by a collaborative board of the best oncologists, best urologist in Germany and the best immunotherapy experts to determine the most effective approach.
Patients from abroad benefit not only from medical expertise but also from full logistical support provided by TIG. Services include appointment scheduling, document translation, visa assistance, and accommodation. For many international patients, affordable treatment in Germany provides a cost-effective alternative to treatment in their home country, without compromising quality or safety.
TACP (Transarterial Chemoperfusion) Treatment for Stage 4 Prostate Cancer in Germany
TACP Treatment in Germany offers a targeted, minimally invasive approach for metastatic prostate cancer in Germany, especially when the disease has spread to the liver or pelvic area, Transarterial Chemoperfusion (TACP) delivers high-dose chemotherapy directly to the tumor through its arterial blood supply without blocking blood flow, allowing repeat sessions with reduced side effects.
Led by Prof. Vogl at Frankfurt Germany, the procedure begins with a consultation and imaging assessments such as CT scans or MRI. These scans map the tumor’s blood vessels, guiding catheter placement.
During treatment, a catheter is inserted into the artery feeding the tumor, and chemotherapy is delivered directly to the site. The session typically lasts one to two hours under local anesthesia. After a short recovery period, patients undergo a follow-up scan to evaluate treatment accuracy and tumor response.
The cost of TACP treatment in Germany ranges from €8,000 to €9,000 per session, depending on tumor characteristics. This therapy is ideal for international patients seeking personalized care at advanced German healthcare centers, with complete logistical support provided by TIG (Treatment in Germany).
Dendritic Cell Immunotherapy for Stage 4 Prostate Cancer in Germany
Dendritic Cell Immunotherapy for prostate cancer in Germany is a form of personalized immunotherapy that activates the patient’s immune system to target cancer cells. It is particularly beneficial for stage 4 cancer patients whose cancer has spread widely and requires systemic immune surveillance.
Under the leadership of Prof Gansauge in Berg, the process begins with a blood draw to isolate monocytes. These are transformed into dendritic cells in a laboratory under EU-GMP conditions and exposed to prostate cancer-specific antigens. The resulting vaccine is reinfused into the patient, where it trains T-cells to recognize and destroy cancer cells. The cost of dendritic cell therapy in Germany is €24,000, covering the entire process including cell preparation, vaccine development, and infusion. Side effects of dendritic cell therapy are usually mild, including temporary fatigue, low-grade fever, or redness at the injection site.
Lutetium-177 PSMA Therapy for Stage 4 Prostate Cancer in Germany
Lutetium-177 PSMA Therapy for stage 4 prostate cancer is a radioligand therapy that specifically targets cells expressing PSMA, a surface protein highly prevalent in advanced prostate cancer. It is recommended when cancer has spread extensively and when systemic therapies alone are insufficient. Patients seeking radiation therapy for prostate cancer in Germany can consider this innovative approach, which is often part of ongoing clinical trials for prostate cancer in Germany to evaluate its effectiveness and safety.
This treatment is led by Prof. Dr. Stefan Dresel, a specialist in nuclear medicine. Before therapy, PET-CT imaging is used to confirm PSMA receptor expression. The patient is then infused with a compound containing Lutetium-177 attached to a PSMA-binding molecule. This delivers localized beta radiation to destroy cancer cells while minimizing damage to surrounding tissue. The cost of Lutetium-177 PSMA Therapy in Germany is €19,000 per session, including imaging, infusion, and monitoring. Side effects are usually manageable, such as fatigue, dry mouth, or transient nausea.
Actinium-225 PSMA Therapy for Stage 4 Prostate Cancer in Germany
Actinium-225 PSMA Therapy for prostate cancer in Germany is a more potent radioligand treatment reserved for cases where patients do not respond to previous therapies. Actinium-225 emits alpha particles, which have a higher energy and shorter path, making them effective at eliminating resistant cancer cells in micro-metastatic sites.
This therapy is led by Prof. Dr. Stefan Dresel. Following PSMA confirmation through imaging, the Actinium-225 compound is administered intravenously. Its targeted action makes it highly effective in stage 4 cases with widespread disease.
The cost of Actinium-225 PSMA Therapy in Germany ranges between €18,000 and €20,000 per session. Most patients tolerate the therapy well, with side effects including fatigue or dry mouth. Its precision and efficacy make it a valuable option in advanced prostate cancer management.
Monitoring and Follow-up
Ongoing evaluation is essential after therapy. German hospitals follow structured protocols involving PSA testing and imaging. Rising PSA level after prostate cancer treatment may suggest biochemical recurrence or progression, requiring immediate reassessment of therapy. Continuous monitoring ensures timely adjustments and long-term disease control.
Why Choose Germany for stage 4 Prostate Cancer Treatment?
Germany is internationally recognized for its advanced healthcare system and its commitment to precision oncology. The country offers access to the most innovative treatments for stage 4 prostate cancer, led by renowned specialists such as Prof. Vogl, Prof. Gansauge, and Prof. Dr. Stefan Dresel.
Germany’s hospitals are equipped with state-of-the-art diagnostic tools, such as PSA tests, MRI, and CT scans, which help doctors accurately monitor the disease and develop a personalized treatment plan. Additionally, Treatment in Germany (TIG) www.treatmentingermany.de provides complete logistical support for international patients, handling travel, lodging, and medical visa arrangements if required, ensuring a seamless treatment experience.
🌍Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained:
Frequently Asked Questions
What is stage 4 prostate cancer?
It refers to cancer that has spread beyond the prostate to distant organs such as the bones, liver, or lymph nodes.
Can stage 4 prostate cancer be treated?
Yes. While it may not be curable, it is manageable with therapies such as Dendritic Cell Immunotherapy in Germany, TACP Treatment in Germany, Lutetium-177, and Actinium-225 PSMA Therapy.
Who provides these treatments in Germany?
Prof. Dr. Frank Gansauge performs dendritic cell therapy, Prof. Vogl leads TACP therapy, and Prof. Dr. Stefan Dresel administers Lutetium-177 and Actinium-225 therapies.
How much does dendritic cell therapy cost in Germany?
The cost of dendritic cell therapy in Germany is €24,000, covering the full cycle from cell processing to administration.
What is the price for Lutetium-177 PSMA therapy?
The approximate cost is €19,000 per cycle, including imaging and treatment.
What are the side effects of dendritic cell therapy?
Side effects of dendritic cell therapy are mild and short-term, such as fatigue, slight fever, or local reactions.
How many sessions of innovative treatment are needed for advanced prostate cancer?
The number of treatment sessions required depends on the therapy and individual response.
Is Dendritic Cell Immunotherapy FDA-approved?
Dendritic Cell Immunotherapy is not FDA-approved in USA but follows EU-GMP standards for safety and effectiveness in Germany.
Can international patients receive treatment for stage 4 prostate cancer in Germany?
Yes. Treatment in Germany (TIG) provides support for international patients, including logistical coordination and medical visa assistance if needed.
Why choose Germany for advanced prostate cancer care?
Germany offers Innovative Treatment, expert-led care, comprehensive diagnostics, and affordable treatment in Germany supported by regulated systems and experienced medical staff.
What if PSA level start rising again?
If the PSA level starts rising again, it may indicate that the prostate cancer has become active or resistant to the current treatment. In such cases, doctors usually recommend re-evaluation with PET/CT or PSMA scans to identify possible tumor progression.
Kindly complete the form below, and our dedicated team will reach out to you promptly. We look forward to connecting with you soon!
Trierer Straße, 56072 Koblenz, Germany
Our benefits:
.webp)
.webp)
 (1).webp)
 (1).webp)
